2024 Castle biosciences stock - The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.

 
Castle Biosciences. Manufacturing · Texas, United States · 342 Employees. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Castle Biosciences is headquartered in Friendswood, Texas with operations in Phoenix, Arizona. Read More. View Company Info for Free. Castle biosciences stock

Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)... Castle Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall …Future criteria checks 1/6. Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.Ellen Goldberg CSTL stock SEC Form 4 insiders trading. Ellen has made over 4 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently Ellen exercised 440 units of CSTL stock worth $7,911 on 14 July 2023.440 units of CSTL stock worth $7,911 on 14 July 2023.6 Mar 2023 ... Today's Castle Biosciences Inc Share Price - Explore CSTL stock Information, latest price chart, peers growth, market trend and start ...Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. Nov 11, 2021 · The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to ... Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price. Nov 30, 2023 · A high-level overview of Castle Biosciences, Inc. (CSTL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...Castle Biosciences Inc Registered Shs's market capitalization is $534.59 M by 26.91 M shares outstanding. Castle Biosciences Stock Snapshot 16.00Castle Biosciences Stock Down 0.1 %. NASDAQ:CSTL opened at $19.97 on Monday. Castle Biosciences, Inc. has a 52 week low of $9.26 and a 52 week high of $29.59. The company’s 50 day moving average ...Ms. Aspinall CSTL stock SEC Form 4 insiders trading. Mara has made over 10 trades of the Castle Biosciences stock since 2017, according to the Form 4 filled with the SEC. Most recently she exercised 3,825 units of CSTL stock worth $68,774 on 2 June 2023.. The largest trade she's ever made was buying 6,000 units of Castle Biosciences …Castle Biosciences stock declined 14% over a five-day trading period ending 3/10/2021, compared to a broader market (S&P500) rise of 2.3%; A change of -14% or more over five trading days is a 4% ...Dec 4, 2023 · Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ... Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher test in patients with Barrett's esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) …Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 22.91% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Dec 4, 2023 · Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ... Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks …The estimated Net Worth of Mara G. Aspinall is at least 2.53 百万$ dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over 1,731,228$ and over the last 8 years she sold CSTL stock worth over 494,800$. In addition, she makes 302,714$ as Independent Director at Castle Biosciences.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically …Shares of Castle Biosciences, Inc. have returned +1.9% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it ...Castle Learning Online’s products don’t come with ready-made answer keys, but they do provide instant feedback and answers once the student has gone through an assignment.6 hours ago · Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx-Melanoma in patients diagnosed with cutaneous melanoma. Jun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months. Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences. At closing, Castle will pay $65.0 million in initial consideration to AltheaDx ...The Castle Biosciences, Inc. stock price gained 1.95% on the last trading day (Wednesday, 29th Nov 2023), rising from $19.48 to $19.86. During the last trading day the stock fluctuated 3.77% from a day low at $19.61 to a day high of $20.35. The price has risen in 7 of the last 10 days and is up by 3.76% over the past 2 weeks.Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.84 Market Cap $537.94 M Shares Outstanding 26.91 M Public Float 24.91 M Yield CSTL is not currently paying a regular dividend. Latest Dividend N/A...On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...Castle Biosciences, Inc. (CSTL) Stock Price | Stock Quote Nasdaq - MarketScreener CASTLE BIOSCIENCES, INC. PDF Report Castle Biosciences, Inc. Stock price …Nov 24, 2023 · Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. Nov 27, 2023 · Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47. In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.2 Ağu 2023 ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ... stock-based compensation expense, change in fair value of contingent ...CSTL Castle Biosciences, Inc. Stock Price & Overview 2.63K followers $19.99 0.13 ( +0.65%) 4:00 PM 11/30/23 NASDAQ | $USD | Post-Market: $19.99 4:17 …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes.Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,070 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...Castle Biosciences Inc. Watch list Set a price target alert After Hours Last Updated: Nov 3, 2023 5:21 p.m. EDT Delayed quote $ 17.95 -0.03 -0.17% After Hours Volume: 7.02K Advanced Charting... Studies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes1-5 Castle’s...The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.00 average price target, implying a 67.49% upside from current levels.The all-time high Castle Biosciences stock closing price was 97.33 on February 09, 2021. The Castle Biosciences 52-week high stock price is 29.59, which is 64.4% above the current share price. The Castle Biosciences 52-week low stock price is 9.26, which is 48.6% below the current share price. The average Castle Biosciences stock price for the ...Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued.PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRASG12C mutation has attracted special interest because it is now considered potentially druggable with recently developed covalent small-molecule KRASG12C inhibitors. …Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Find the latest Interpace Biosciences, Inc. (IDXG) stock quote, history, news and other vital information to help you with your stock trading and investing.Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks to Buy Now Castle Biosciences, Inc. (NASDAQ ...White Castle does not allow for the purchase of franchises. Each of the restaurants is privately owned and operated through the White Castle parent company. Because the company is privately owned, it doesn’t offer stock options to the publi...Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ...Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically …Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a ... Employment: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Chimeric antigen receptors (CARs) and CAR-expressing T cells are provided that can specifically target cells that express an elevated level of a target antigen. Likewise, methods for specifically targeting …But note: Castle Biosciences may not be the best stock to buy.So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).. Please note, the ...Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …Dec 1, 2023 · Stock Info Stock Quote Price $19.88 Volume 52,546 Change +0.03 % Change +0.15% Today's Open $19.69 Previous Close $19.85 Intraday High $20.26 Intraday Low $19.69 52-Week High $29.59 52-Week Low $9.26 Pricing delayed by 20 minutes. Last Updated 11/24/2023 1:00 PM ET Stock Chart View stock chart as data table From: To: Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...Castle Biosciences (CSTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 2. Analyst Catherine Ramsey Schulte from Robert W. Baird remains ...The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.On average, Wall Street analysts predict. that Castle Biosciences's share price could reach $32.13 by Aug 4, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 63.57% from the current CSTL share price of $19.64. 2 Ağu 2023 ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health ... stock-based compensation expense, change in fair value of contingent ...Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend.19 Nis 2023 ... Castle Biosciences, Inc., a company improving health through innovative ... Stock BITF logo. BITF · Bitfarms Announces C$60 Million Private ...Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.At closing, Castle will pay $30 million in initial consideration to Cernostics security holders, which may consist entirely of cash or $20 million in cash and $10 million in common stock of Castle ...4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00.19 Nis 2023 ... Castle Biosciences, Inc., a company improving health through innovative ... Stock BITF logo. BITF · Bitfarms Announces C$60 Million Private ...Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …Oct 31, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ... 11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma. The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Jun 5, 2023 · Castle Biosciences Inc (CSTL) stock is down -47.58% while the S&P 500 has gained 0.08% as of 10:52 AM on Monday, Jun 5. CSTL is lower by -$10.81 from the previous closing price of $22.73 on volume of 2,678,434 shares. Over the past year the S&P 500 is up 3.99% while CSTL is lower by -44.69%. CSTL lost -$2.71 per share the over the last 12 months. On average, Wall Street analysts predict. that Castle Biosciences's share price could reach $32.13 by Aug 4, 2024. The average Castle Biosciences stock price prediction forecasts a potential upside of 63.57% from the current CSTL share price of $19.64.Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 22.91% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe …Castle biosciences stock

The estimated Net Worth of Mara G. Aspinall is at least $2.81 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $2,014,618 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.. Castle biosciences stock

castle biosciences stock

Belgium, a country known for its rich history, stunning architecture, and vibrant culture, offers a plethora of attractions for visitors to explore. From medieval castles to modern art galleries, Belgium has something for everyone.Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...AltheaDx filed for an initial public stock offering in December 2014 but shelved the proposed stock sale in early 2015. Castle Biosciences, which went public in 2019, makes tests that help guide ...Castle Biosciences Market Cap: 537.40M, Enterprise value: 484.98M, P/E: -8.76, PEG ratio: 0.08, EPS: -2.84, Revenue: 192.00M, EBITDA: -64.35M, ...Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks …Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 22.91% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ...Jul 11, 2023 · Castle Biosciences makes tests for patients diagnosed with certain diseases to help evaluate optimal treatment options. Read my analysis of CSTL stock here. ... Castle stock had fallen to ~$33 per ... Tobin Juvenal CSTL stock SEC Form 4 insiders trading. Tobin has made over 5 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Tobin exercised 6,173 units of CSTL stock worth $14,753 on 1 March 2023.6,173 units of CSTL stock worth $14,753 on 1 March 2023.Nov 2, 2023 · Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide. Forecst.com predicts future values using technical analysis of a large number of analytical parameters. CSTL stock returns are also predicted based on historical data. According to our research, CSTL stock is a bad long-term investment. CSTL share price has been in a bear cycle for the past year. Castle Biosciences, Inc. stock trend is …View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Castle Biosciences’ technology approach objectively measures optimal combinations of epithelial, immune, and stromal processes in the context of tissue morphology to extract tissue profiles (information from digital whole side images of tissue biopsies) that are correlated with diagnosis and prognosis. Our tissue systems biology approach integrates …CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million.Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ... November 22, 2023 at 3:28 AM · 2 min read. Last week, Castle Biosciences, Inc. ( NASDAQ:CSTL) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares ...Castle Biosciences had a GAAP loss of 70 cents a share, approximately 20 cents a share above expectations. Revenues rose 44% on a year-to-year basis to $50.1 million, almost $6 million over the ...The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.Materials used to build castles include earth, wood and stone. Motte-and-bailey castles were made of earth and wood, but due to weaknesses in these castles, stone castles were created.Nov 16, 2023 · Nikkei 225. 33,424.41. -0.28%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Castle Biosciences Inc (CSTL.OQ) real-time stock quotes, news, price and financial information from ... Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …Jun 5, 2023 · S hares of Castle Biosciences (NASDAQ: CSTL) were down more than 47% on Monday afternoon as three analysts lowered their price targets for the medical diagnostic stock. The healthcare stock is ... On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...Jul 13, 2023 · Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ... Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.Howl’s Moving Castle is a beloved Japanese animated film that has captured the hearts of audiences worldwide since its release in 2004. Based on the novel by Diana Wynne Jones, the film tells the story of a young woman named Sophie who is c...Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …Jun. 03, 2022 5:05 PM ET Castle Biosciences, Inc. (CSTL) SA Transcripts. 140.86K Follower s. The following slide deck was published by Castle Biosciences, Inc. in conjunction with this event. View ...Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …31 Eki 2023 ... About Castle Biosciences Inc (CSTL). Before we jump into Castle Biosciences Inc's stock price, history, target price and what caused it to ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a paper in Clinical, Cosmetic and Investigational Dermatology highlighting a clinician-derived, real-world algorithm that provides a framework to incorporate DecisionDx®-SCC test results …Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersThe estimated Net Worth of Frank Stokes is at least $2.05 Million dollars as of 4 April 2023. Mr. Stokes owns over 4,000 units of Castle Biosciences stock worth over $556,435 and over the last 3 years he sold CSTL stock worth over $0. In addition, he makes $1,498,230 as Chief Financial Officer at Castle Biosciences.Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …Castle Biosciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. CSTL updated stock price target summary.Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that the Company's medical director, Matthew ...The estimated Net Worth of Mara G. Aspinall is at least $1.28 million dollars as of 2 June 2023. Ms. Aspinall owns over 3,825 units of Castle Biosciences stock worth over $485,681 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for 25.00 expecting CSTL to rise to within 12 ...FRIENDSWOOD - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data on DecisionDx-Melanoma and DecisionDx-UM will be shared during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6.NASDAQ: CSTL + 19.38 -0.68 ( -3.39% ) Minimum 20 minutes delayed November 21, 2023 4:00 PM Overview Castle Biosciences is improving health through …The 31-GEP test (DecisionDx-Melanoma; Castle Biosciences Inc, Friendswood, TX) was used to analyze the expression of 27 prognostic genes (28 probes) and three control genes from primary CM tumors, as previously described. 21 All 31-GEP testing was performed in a College of American Pathologists–accredited and Clinical Laboratory Improvement ...NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.51 -0.27 (-1.37%) As of 03:38PM EST. Market open. 1d 5d 1m 6m YTD 1y 5y Max Full screen …Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.47 per share a year ago.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price. Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business. Mr. Spiess CSTL stock SEC Form 4 insiders trading. Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $29,070 on 10 December 2021.. The largest trade he's ever made was selling 40,000 units of Castle …Castle Biosciences’ technology approach objectively measures optimal combinations of epithelial, immune, and stromal processes in the context of tissue morphology to extract tissue profiles (information from digital whole side images of tissue biopsies) that are correlated with diagnosis and prognosis. Our tissue systems biology approach integrates …The estimated Net Worth of David S Kabakoff is at least $76.2 Million dollars as of 17 June 2021. David Kabakoff owns over 30,000 units of Castle Biosciences stock worth over $11,536,949 and over the last 4 years he sold CSTL stock worth over $64,362,650. In addition, he makes $288,339 as Independent Director at Castle …Leadership: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Patents with Castle Biosciences. No other potential conflicts of interest were reported. OPTIONS & TOOLS. Export Citation: Track Citation: Add To Favorites: Rights & Permissions; COMPANION …Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...Tobin Juvenal CSTL stock SEC Form 4 insiders trading. Tobin has made over 5 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently Tobin exercised 6,173 units of CSTL stock worth $14,753 on 1 March 2023.6,173 units of CSTL stock worth $14,753 on 1 March 2023.DOI: 10.1200/JOP.2017.022152 Journal of Oncology Practice - published online before print March 28, 2017 . PMID: 28350513May 30, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 8.79% so far this month. During the month of May, Castle Biosciences Inc’s stock price has reached a high of $26.70 and a low of $20.56. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $15.58. Year to date ... Castle Learning Online’s products don’t come with ready-made answer keys, but they do provide instant feedback and answers once the student has gone through an assignment.Castle Biosciences to Participate in Upcoming Investor Conferences. FRIENDSWOOD, Texas-- (BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle …Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new discovery data from an ongoing study exploring the potential for developing a complementary, minimally invasive test to evaluate small, suspicious lesions of uncertain malignant potential in patients’ eyes.The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.Which Castle Biosciences insiders have been selling company stock? The following insiders have sold CSTL shares in the last 24 months: Daniel Bradbury ($6,274,776.69), and Derek J Maetzold ($1,265,588.97).Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I cutaneous melanoma …Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.May 30, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 8.79% so far this month. During the month of May, Castle Biosciences Inc’s stock price has reached a high of $26.70 and a low of $20.56. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $15.58. Year to date ... Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma .... Enzo float